Assetmark Inc. Has $2.13 Million Holdings in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Assetmark Inc. raised its stake in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 9.1% during the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 43,906 shares of the company’s stock after purchasing an additional 3,650 shares during the quarter. Assetmark Inc.’s holdings in Amphastar Pharmaceuticals were worth $2,131,000 as of its most recent filing with the SEC.

A number of other large investors have also made changes to their positions in the stock. Silvercrest Asset Management Group LLC raised its stake in shares of Amphastar Pharmaceuticals by 35.1% in the first quarter. Silvercrest Asset Management Group LLC now owns 112,428 shares of the company’s stock valued at $4,937,000 after purchasing an additional 29,182 shares in the last quarter. International Assets Investment Management LLC bought a new position in shares of Amphastar Pharmaceuticals during the 3rd quarter worth about $11,070,000. Intech Investment Management LLC acquired a new stake in shares of Amphastar Pharmaceuticals during the 2nd quarter valued at about $426,000. Granite Investment Partners LLC increased its stake in Amphastar Pharmaceuticals by 12.7% in the second quarter. Granite Investment Partners LLC now owns 397,514 shares of the company’s stock valued at $15,901,000 after acquiring an additional 44,744 shares during the period. Finally, 1620 Investment Advisors Inc. acquired a new position in Amphastar Pharmaceuticals in the second quarter worth about $93,000. Institutional investors and hedge funds own 65.09% of the company’s stock.

Insiders Place Their Bets

In related news, EVP Yakob Liawatidewi sold 5,214 shares of the stock in a transaction that occurred on Wednesday, November 6th. The stock was sold at an average price of $52.05, for a total transaction of $271,388.70. Following the completion of the sale, the executive vice president now directly owns 74,938 shares of the company’s stock, valued at approximately $3,900,522.90. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other news, CFO William J. Peters sold 7,426 shares of the stock in a transaction dated Wednesday, November 6th. The shares were sold at an average price of $52.05, for a total transaction of $386,523.30. Following the completion of the transaction, the chief financial officer now directly owns 94,103 shares in the company, valued at $4,898,061.15. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Yakob Liawatidewi sold 5,214 shares of the firm’s stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $52.05, for a total value of $271,388.70. Following the completion of the transaction, the executive vice president now owns 74,938 shares of the company’s stock, valued at approximately $3,900,522.90. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 31,533 shares of company stock worth $1,571,652. Corporate insiders own 27.10% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently weighed in on AMPH. Needham & Company LLC reiterated a “hold” rating on shares of Amphastar Pharmaceuticals in a research note on Thursday, August 8th. Piper Sandler lowered their price target on Amphastar Pharmaceuticals from $71.00 to $66.00 and set an “overweight” rating on the stock in a research report on Thursday, August 8th. Finally, StockNews.com lowered Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, November 1st. Three analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $63.00.

Amphastar Pharmaceuticals Trading Down 4.7 %

NASDAQ:AMPH opened at $45.48 on Thursday. The firm has a market capitalization of $2.19 billion, a price-to-earnings ratio of 15.16, a PEG ratio of 0.92 and a beta of 0.82. Amphastar Pharmaceuticals, Inc. has a 1-year low of $36.56 and a 1-year high of $65.92. The business’s 50-day moving average price is $48.42 and its two-hundred day moving average price is $44.34. The company has a current ratio of 3.43, a quick ratio of 2.61 and a debt-to-equity ratio of 0.82.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.